Reported Saturday, Aileron Therapeutics To Present Phase 1b Trial Data On LTI-03 For Idiopathic Pulmonary Fibrosis At 22nd Lung Fibrosis Colloquium

據報道，Aileron Therapeutics將在第22屆肺纖維化研討會上發佈LTI-03用於特發性肺纖維化的第10億期試驗數據

Benzinga · 2024/10/14 03:27

First scientific presentation of previously announced data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating low-dose LTI-03 (2.5 mg BID) in IPF, affirms positive trends in seven of the eight biomarkers evaluated, suggesting potential therapeutic effect
Recently completed enrollment of Cohort 2 evaluating high-dose LTI-03 (5 mg BID) in mid-September; topline data expected in the near-term

對正在進行的第10億臨床試驗中Cohort 1中低劑量LTI-03（2.5 mg 買盤）的先前公佈數據進行首次科學表達，肺纖維化患者八項生物標誌物中有七項呈現積極趨勢，暗示潛在療效
最近完成了Cohort 2的高劑量LTI-03（5 mg 買盤）的入組評估，預計在短期內公佈上線數據

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息